You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Request a contact

Stay informed

Live Chat

ViiV Healthcare @ IAS 2017

ViiV Healthcare held a webinar to discuss abstracts presented at the IAS 2017 conference in Paris.
Dr. Michael Aboud and Dr. Jean Van Wyk from ViiV Healthcare will present a selection of Dolutegravir▼ (DTG) data.

Angelina Namiba, Project Manager at the Salamander Trust and member of the multi-disciplinary Steering Committee of the Positive Perspectives Study, will share the results of this international patient survey.

Chapter 1: Introduction & DAWNING Study

Video player requires JavaScript enabled. You can download this video here: https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/MP4/hiv_iedgr003717_meettheexpert_ias_chaper1.mp4 https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/WEBM/hiv_iedgr003717_meettheexpert_ias_chaper1.webm https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/OGV/hiv_iedgr003717_meettheexpert_ias_chaper1.ogv

Presented by Dr. Michael Aboud, Vice President and Global Medical Lead, ViiV Healthcare.

Chapter 2: NEAT022 Study

Video player requires JavaScript enabled. You can download this video here: http://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/MP4/hiv_iedgr003717_meettheexpert_ias_chaper2.mp4 http://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/WEBM/hiv_iedgr003717_meettheexpert_ias_chaper2.webm http://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/OGV/hiv_iedgr003717_meettheexpert_ias_chaper2.ogv

Presented by Dr. Jean Van Wyk, Global Medical Affairs Director, ViiV Healthcare

Chapter 3: OPERA® Women’s analysis

Video player requires JavaScript enabled. You can download this video here: https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/MP4/hiv_iedgr003717_meettheexpert_ias_chaper3.mp4 https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/WEBM/hiv_iedgr003717_meettheexpert_ias_chaper3.webm https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/OGV/hiv_iedgr003717_meettheexpert_ias_chaper3.ogv

Presented by Dr. Jean Van Wyk, Global Medical Affairs Director, ViiV Healthcare

Chapter 4: Positive Perspectives Survey Results & Insights

Video player requires JavaScript enabled. You can download this video here: https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/MP4/hiv_iedgr003717_meettheexpert_ias_chaper4.mp4 https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/WEBM/hiv_iedgr003717_meettheexpert_ias_chaper4.webm https://gskvideo.edgesuite.net/HealthSites/Health/Ireland/HCP/HIV/OGV/hiv_iedgr003717_meettheexpert_ias_chaper4.ogv

Presented by Angelina Namiba, Salamander Trust, UK

TRIUMEQ ▼ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

TIVICAY ▼ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults, adolescents and children aged 6 years and over, weighing at least 15kg.

Triumeq▼

(dolutegravir/abacavir/lamivudine)

Product information

Prescribing information

Tivicay▼

(dolutegravir)

Product information

Prescribing information

References:

  1. Aboud et al. IAS 2017; Paris, France. Slides TUAB0105LB.
  2. Gatell et al. NeatID. Slides. NEAT22/SSAT060 week 48 data
  3. Carpio et al. IAS Poster. Paris. WEPEB0573.
  4. Murungi A et al. IAS Poster. Paris WEPED1423.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.